Mary High
Adult Health · Wilmington, DENPI 1457350019
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 469 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 18.5% — the pattern of someone who eats at a lot of different presentations. Among adult health clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 469 payments — averaging $18.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AbbVie$2K
- Lilly USA, LLC$816
- AstraZeneca$703
- GSK$615
- Pfizer$391
- plus $3K from 29 others
What the payments were for
- Food & beverage$8,473100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 96 | $1,569 |
| AbbVie(2 entities) | 81 | $1,559 |
| Lilly USA, LLC | 47 | $816 |
| AstraZeneca | 37 | $703 |
| GSK | 37 | $615 |
| Pfizer | 24 | $391 |
| Axsome Therapeutics, Inc. | 16 | $365 |
| Astellas Pharma US Inc | 21 | $322 |
| Merck | 14 | $200 |
| Otsuka America Pharmaceutical, Inc. | 10 | $190 |
| Abbott | 10 | $182 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $175 |
| Idorsia Pharmaceuticals US Inc | 4 | $174 |
| Biohaven Pharmaceuticals, Inc. | 5 | $161 |
| Medtronic | 4 | $133 |
| Exact Sciences | 6 | $117 |
| Bayer | 6 | $103 |
| Alkermes, Inc. | 5 | $93 |
| Eisai Inc. | 5 | $82 |
| Boehringer Ingelheim | 4 | $71 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $53 |
| VBI Vaccine (delaware) Inc. | 2 | $52 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $50 |
| Sunovion Pharmaceuticals Inc. | 3 | $46 |
| Sanofi-aventis U.S. LLC | 2 | $41 |
| Braeburn Inc. | 2 | $31 |
| Corium, LLC | 1 | $30 |
| Tactile Systems Technology Inc | 1 | $30 |
| Phathom Pharmaceuticals, Inc. | 2 | $26 |
| Neurocrine Biosciences, Inc. | 1 | $22 |
| Insulet Corporation | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Dexcom, Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Impel Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Saxenda$120
- UBRELVY$118
- NURTEC ODT$109
- QUVIVIQ$109
How this compares
$8,486 in reported general payments places this provider in the 95th percentile of 65 adult health providers in Delaware.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 85 | $111,932 |
| MounjaroTirzepatide | 57 | $82,428 |
| JardianceEmpagliflozin | 26 | $40,621 |
| JanuviaSitagliptin Phosphate | 24 | $34,937 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $23,393 |
| EliquisApixaban | 17 | $18,373 |
| FarxigaDapagliflozin Propanediol | 18 | $18,181 |
| XareltoRivaroxaban | 14 | $11,342 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $7,048 |
| Omega-3 Acid Ethyl Esters | 19 | $3,108 |
| Rosuvastatin Calcium | 122 | $2,774 |
| Omeprazole | 137 | $2,580 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $2,433 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 92 | $2,365 |
| Levothyroxine Sodium | 210 | $2,273 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,569 | $111,93285 claims |
| Lilly USA, LLCMounjaro | $816 | $82,42857 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $71 | $47,66938 claims |
| MerckJanuvia | $200 | $34,93724 claims |
| GSKTrelegy Ellipta | $615 | $23,39325 claims |
| PfizerEliquis | $391 | $18,37317 claims |
| AstraZenecaFarxiga | $703 | $18,18118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 65 adult health providers in Delaware.
Other adult health in Wilmington
- Emily KellerWilmington$26K
- Adrienne WoodsWilmington$2K
- Dannette MitchellWilmington$2K
- Alexandra HarisWilmington$1K
- Mary NairnWilmington$1K
- Aruna MuthukumarWilmington$657
- Ellen BrennanWilmington$528
- Margaret Corrigan MasseyWilmington$513
- Nicole ScottWilmington$267
- Stephanie MoonWilmington$264
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.